*McGovern Medical School at the University of Texas Health Science Center, Houston, Texas;
†Loyola University Chicago Stritch School of Medicine, Maywood, Illinois;
‡Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, New York;
§Vitreous Retina Macula Consultants of New York, New York, New York;
¶Retina Department, Institute of Ophthalmology Fundación Conde de Valenciana, Mexico City, Mexico;
**Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York;
††Icahn School of Medicine at Mount Sinai, New York, New York;
‡‡Hackensack University Medical Center, Hackensack, New Jersey;
§§IHealthscreen Inc., New York, New York;
¶¶Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York;
***Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York; and
†††Department of Ophthalmology, NYU Grossman School of Medicine, New York, New York.
Reprint requests: R. Theodore Smith, MD, PhD, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY 10003; e-mail: [email protected]
Regeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent Blindness Challenge Grant, Macula Foundation (K.B.F.), Bayer-Global Ophthalmology Awards (G.L.G.), and International Council of Ophthalmology-Alcon Fellowship (O.O.M.).
R. B. Rosen is a consultant to OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer, Diopsys, and Teva. He has personal financial interests in Opticology, Guardion, and CellView. K. B. Freund is a consultant to Regeneron, Allergan, Zeiss, Bayer, Heidelberg Engineering, and Novartis. He receives research funding from Genentech/Roche. R. T. Smith is a consultant to Ora Technologies and an equity holder in MacRegen, Inc. None of the other authors has any conflicting interests to disclose.
R. J. Thomson and J. Chazaro contributed equally to this work.
